Epoetin Alfa: uses, dosing, side effects & brands

How epoetin alfa is dosed

From the FDA label for Epogen/Procrit (application BLA103234). Other epoetin alfa products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Evaluate iron status before and during treatment and maintain iron repletion. Correct or exclude other causes of anemia before initiating treatment ( 2.1 ). In pregnant women, lactating women, neonates, infants: Use only single-dose vials ( 2.1 ). Patients with CKD: Initial dose: 50 to 100 Units/kg 3 times weekly (adults) and 50 Units/kg 3 times weekly (pediatric patients). Individualize maintenance dose. Intravenous route recommended for patients on hemodialysis ( 2.2 ). Patients on Zidovudine due to HIV Infection: 100 Units/kg 3 times weekly ( 2.3 ). Patients with Cancer on Chemotherapy: 40,000 Units weekly or 150 Units/kg 3 times weekly (adults); 600 Units/kg intravenously weekly (pediatric patients ≥ 5 years) ( 2.4 ). Surgery Patients: 300 Units/kg per day daily for 15 days or 600 Units/kg weekly ( 2.5 ). 2.1 Important Dosing Information Evaluation of Iron Stores and Nutritional Factors Evaluate the iron status in all patients before and during treatment. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of ESA therapy. Monitoring of Response to Therapy Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) before initiating PROCRIT.…

Epoetin Alfa side effects

Who shouldn’t take epoetin alfa

How long epoetin alfa keeps

The date on a sealed pack is not the only one: some epoetin alfa labels start a second clock once the product is opened or mixed, as short as 21 days.

Epoetin Alfa and breastfeeding

From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.

The excretion of exogenous epoetin alfa (recombinant human erythropoietin; EPO) in breastmilk has not been studied. Erythropoietin is a normal component of human milk. Although some studies have shown an improve response of postpartum anemia when epoetin alfa was used with iron therapy, current consensus is that epoetin alfa has no clinically important effect on the increase in hemoglobin concentration over iron alone. No adverse reactions were reported in the breastfed infants of mothers who received epoetin alfa. Based on theoretical considerations, the manufacturer recommends avoiding the use of epoetin alfa multiple-dose vials for lactating women because of its benzyl alcohol content and to avoid breastfeeding for 2 weeks after a dose that contains benzyl alcohol. No special precautions are required during breastfeeding if mothers receive epoetin alfa from a single-use vial without preservatives.

National Institute of Child Health and Human Development, record revised September 15, 2023. LactMed states its information is not a substitute for professional judgement.

What people report to the FDA about epoetin alfa

The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 3,559 reports naming epoetin alfa, and the FDA flagged 93% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:

• anaemia301 reports
• diarrhoea254 reports
• dyspnoea253 reports
• pneumonia223 reports
• nausea202 reports
• asthenia191 reports
• vomiting186 reports
• hypotension180 reports

Source: openFDA drug/event (FAERS), retrieved July 25, 2026.

Related calculators